Vienna Insurance Group’s C4 Therapeutics CCCC Stock Holding History

Vienna Insurance Group’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$397K	Hold	85,000	–	–	0.1%	27
2026 Q1	$224K	Hold	85,000	–	–	0.09%	28
2025 Q4	$162K	Hold	85,000	–	–	0.08%	26
2025 Q3	$189K	Hold	85,000	–	–	0.11%	26
2025 Q2	$122K	Hold	85,000	–	–	0.08%	88
2025 Q1	$136K	Hold	85,000	–	–	0.07%	93
2024 Q4	$306K	Hold	85,000	–	–	0.18%	85
2024 Q3	$485K	Hold	85,000	–	–	0.21%	91
2024 Q2	$393K	Hold	85,000	–	–	0.15%	94
2024 Q1	$694K	Hold	85,000	–	–	0.27%	95
2023 Q4	$480K	Hold	85,000	–	–	0.22%	91
2023 Q3	$158K	Hold	85,000	–	–	0.07%	91
2023 Q2	$234K	Hold	85,000	–	–	0.11%	88
2023 Q1	$267K	Hold	85,000	–	–	0.16%	88
2022 Q4	$502K	Hold	85,000	–	–	0.39%	33
2022 Q3	$745K	Hold	85,000	–	–	0.53%	35
2022 Q2	$641K	Hold	85,000	–	–	0.43%	36
2022 Q1	$2.06M	Buy	85,000 +40,000	+89%	+$971K	1.16%	32
2021 Q4	$1.45M	Buy	+45,000	New	+$1.78M	0.99%	28

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vienna Insurance Group's CCCC Position: Q2 2026 in Review

Vienna Insurance Group held its C4 Therapeutics (CCCC) position steady in Q2 2026 at 85,000 shares worth $397K. The position accounts for 0.1% of the portfolio, ranked #27.

Vienna Insurance Group first reported a position in CCCC in Q4 2021 and has held it in 19 quarters since. The position peaked at $2.06M in Q1 2022. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Vienna Insurance Group held 85,000 shares of C4 Therapeutics worth $397K as of Q2 2026.
Vienna Insurance Group left its C4 Therapeutics share count unchanged in Q2 2026.
C4 Therapeutics made up 0.1% of Vienna Insurance Group's portfolio in Q2 2026, its #27 holding.
Vienna Insurance Group first reported a position in C4 Therapeutics in Q4 2021 and has held it in 19 quarters since.
Vienna Insurance Group's C4 Therapeutics position peaked at $2.06M in Q1 2022.
147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Vienna Insurance Group's 13F filing for Q2 2026, filed 30 Jul 2026.